Certara

70 articles about Certara

• Certara to Report Fourth Quarter and Full Year 2020 Preliminary Financial Results on March 4, 2021

  2/17/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release preliminary financial results for the fourth quarter and full year of 2020 after the market close on Thursday, March 4, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (833) 360-0946 for do

• Certara Announces Closing of Its Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

  12/16/2020

  Certara, Inc. (“Certara”), a global leader in biosimulation by 2019 revenue, today announced that on December 15, 2020, it closed its upsized initial public offering of 33,413,250 shares of common stock at $23.00 per share. The closing includes 4,358,250 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. Certara sold 14,630,000 shares of its common stock, and certain

• 

  Biopharma Money on the Move: December 9-15

  12/16/2020

  A roundup of life sciences companies raking in the cash.

• Certara Announced Pricing of Its Upsized Initial Public Offering

  12/11/2020

  Certara, Inc. (“Certara”), a global leader in biosimulation, today announced the pricing of its upsized initial public offering of 29,055,000 shares of its common stock at $23.00 per share. Certara is offering 14,630,000 shares of its common stock and certain selling stockholders are offering 14,425,000 shares of common stock in the offering. Shares of Certara’s common stock are expected to begin trading on The Nasdaq Gl

• Certara Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

  10/8/2020

  Certara Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

• Food and Drug Administration Renews and Expands Use of Certara’s Biosimulation Software for Reviewing Regulatory Submissions

  10/1/2020

  Certara, a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has again renewed and expanded its licenses of Certara’s biosimulation software, with more than 400 user licenses of Simcyp™ and Phoenix™ platforms. Eleven divisions and offices of the FDA use Certara’s software for internal resea

• Certara Announces First Enrollee in International Registry to Assess Preventative Therapies in Healthcare Workers Exposed to COVID-19

  8/13/2020

  Certara ® , the global leader in biosimulation, has launched an international registry of healthcare workers to collect information on risk factors for developing COVID-19 and the use of preventative therapies. The International Registry of Healthcare Workers Exposed to COVID-19 (UNITY Global) will enable prevention policies to be

• Certara Announces New COVID-19 Biosimulation Platform and Key Updates to Its Quantitative Systems Pharmacology (QSP) Technology Platforms

  8/10/2020

  Certara®, the global leader in biosimulation, today announced the development of a new biosimulation platform for COVID-19 vaccines and major enhancements in its Immunogenicity and Immuno-oncology QSP platforms. Certara has partnered with leading, global pharmaceutical companies on these advancements

• Certara Launches COVID-19 Clinical Outcomes Database

  7/23/2020

  Research Database to Quantify Impact of Potential COVID-19 Treatments, with Results from Over 500 Clinical Trials and Observational Studies Over the Next Three Months

• Certara Launches Version 8.3 of Phoenix™ Biosimulation Software for Drug Development

  6/24/2020

  Certara®, the global leader in biosimulation, today announced the launch of version 8.3 of its Phoenix ™ platform, the industry gold standard in pharmacokinetic/ pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation softwar